Institut Jean Godinot

Running trials

• Not yet recruiting

  Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers

  NCT07437287· Phase 2/3· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Source

• Recruiting

  Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery

  NCT06476184· Phase 3· Source

• Recruiting

  Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

  NCT06333314· Phase 2· Source

• Recruiting

  Personalized Medicine for Advanced Biliary Cancer Patients

  NCT05615818· Phase 3· Source

• Recruiting

  First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

  NCT06253611· Phase 2· Source

• Recruiting

  A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  NCT06119581· Phase 3· Source

• Recruiting

  TARGETed Therapy Drug MONITOring in DIGestive Oncology

  NCT05443087· Source

• Recruiting

  Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers

  NCT04747054· Phase 3· Source

• Active, not recruiting

  Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients

  NCT03870919· Source

• Recruiting

  Erectile Dysfunction in Good Prognosis Prostate Cancer : Comparison Between Brachytherapy and Stereotactic Body Radiotherapy

  NCT03830788· Source

• Active, not recruiting

  Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases

  NCT03143322· Source

• Active, not recruiting

  Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy

  NCT03418844· Source

• Active, not recruiting

  PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer

  NCT03774732· Phase 3· Source

• Recruiting

  Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)

  NCT03848052· Source

• Active, not recruiting

  Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

  NCT02947685· Phase 3· Source

• Recruiting

  Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008

  NCT03275311· Source

• Active, not recruiting

  A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

  NCT01957436· Phase 3· Source

• Recruiting

  COsegregation of VARiants in Panel of Genes

  NCT01689584· Source

• Recruiting

  French Childhood Cancer Survivor Study

  NCT01620372· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Liver and biliary tract cancer3 recruiting
• Lung cancer3 recruiting
• Colorectal cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Neuroendocrine tumours2 recruiting
• Ovarian cancer2 recruiting
• Pancreatic cancer2 recruiting
• Prostate cancer2 recruiting
• Childhood cancers1 recruiting
• Endometrial cancer1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme

  NCT06475352· Phase 2· Source

• Completed

  Impact on Quality of Life and Health of the CONTINUUM+ CONNECT Remote Monitoring Solution

  NCT06379880· Source

• Completed

  A NON-INTERVENTIONAL STUDY ON AVELUMAB USE IN PATIENTS WITH ADVANCED OR METASTATIC UROTHELIAL CARCINOMA

  NCT04822350· Source

• Terminated

  Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer

  NCT04450836· Phase 2· Source

• Completed

  Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

  NCT04263051· Phase 2· Source

• Completed

  COL Immunotherapy Before Radiochimio + Ipilimumab

  NCT04256213· Source

• Completed

  Study of DS-8201a, an Antibody Drug Conjugate for Advanced Breast Cancer Patients, With Biomarkers Analysis

  NCT04132960· Phase 2· Source

• Completed

  Retarded Surgery Following Neoadjuvant Chemotherapy in Advanced Ovarian Cancer

  NCT03579394· Source

• Terminated

  Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

  NCT03412058· Source

• Completed

  PEMBRO With Chemo in Neo Adj Treatment of Ovarian Cancer .

  NCT03275506· Phase 2· Source

• Completed

  Modulation of Anti-tumor T Cell Responses in Cancer Patients Treated by Concomitant Radiochemotherapy

  NCT03117946· Source

• Completed

  PHASE III RANDOMISED TRIAL to EVALUATE FOLFOX with or WITHOUT DOCETAXEL (TFOX) AS 1st LINE CHEMOTHERAPY for LOCALLY ADVANCED or METASTATIC OESOPHAGO-GASTRIC CARCINOMA

  NCT03006432· Phase 3· Source

• Completed

  Impact of Chemo-induced Menopause on Quality of Life in Women <45 Years Old, Diagnosed With Non-metastatic Breast Cancer

  NCT02102568· Source